Qiming U.S. Ventures Management’s Ventyx Biosciences VTYX Stock Holding History

Qiming U.S. Ventures Management’s Portfolio VTYX Stock Details VTYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-412,225	Closed	-$882K	–	6
2025 Q2	$882K	Hold	412,225	–	–	3.74%	4
2025 Q1	$474K	Hold	412,225	–	–	2.05%	5
2024 Q4	$903K	Hold	412,225	–	–	1.77%	4
2024 Q3	$899K	Hold	412,225	–	–	1.75%	5
2024 Q2	$952K	Hold	412,225	–	–	1.81%	5
2024 Q1	$2.27M	Sell	412,225 -274,145	-40%	-$1.25M	2.53%	5
2023 Q4	$1.7M	Hold	686,370	–	–	1.55%	6
2023 Q3	$23.8M	Sell	686,370 -60,000	-8%	-$2.07M	31.65%	2
2023 Q2	$24.5M	Hold	746,370	–	–	25.72%	2
2023 Q1	$25M	Hold	746,370	–	–	30.26%	1
2022 Q4	$24.5M	Hold	746,370	–	–	32.37%	2
2022 Q3	$26.1M	Sell	746,370 -163,936	-18%	-$3.63M	37.85%	1
2022 Q2	$11.1M	Hold	910,306	–	–	15.45%	4
2022 Q1	$12.4M	Hold	910,306	–	–	11.6%	5
2021 Q4	$18.1M	Buy	+910,306	New	+$17.3M	8.32%	4

Other funds holding VTYX

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Qiming U.S. Ventures Management's VTYX Position: Q3 2025 in Review

Qiming U.S. Ventures Management sold out of Ventyx Biosciences (VTYX) in Q3 2025, closing a stake of 412,225 shares — an estimated $882K sold.

Qiming U.S. Ventures Management first reported a position in VTYX in Q4 2021 and held it in 15 quarters. The position peaked at $26.1M in Q3 2022. 110 funds tracked by Wall St. Rank hold VTYX as of Q3 2025.

Qiming U.S. Ventures Management reported no remaining Ventyx Biosciences position as of Q3 2025 after selling out during the quarter.
Qiming U.S. Ventures Management sold 412,225 Ventyx Biosciences shares in Q3 2025, an estimated $882K.
Qiming U.S. Ventures Management first reported a position in Ventyx Biosciences in Q4 2021 and held it in 15 quarters.
Qiming U.S. Ventures Management's Ventyx Biosciences position peaked at $26.1M in Q3 2022.
110 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q3 2025.

Based on Qiming U.S. Ventures Management's 13F filing for Q3 2025, filed 10 Nov 2025.